FDA Director-General Eric Domingo presents data on adverse events following immunization during a virtual media forum on Thursday. Photo courtesy: screenshot from DOH Kapihan

FDA Director-General Eric Domingo. Photo courtesy: screenshot from DOH Kapihan

MANILA, Philippines — The Food and Drug Authority (FDA) has put up a special lane to expedite the emergency use approvals of drugs for the treatment of COVID-19.

FDA Director-General Eric Domingo on Wednesday said this will allow them to prioritize COVID-19 drugs and fast-track their approvals.

So far, Domingo said the FDA approved two more brands of the anti-inflammatory drug tocilizumab.

It has also approved three brands of baricitinib, a drug for the treatment of rheumatoid arthritis in adults that can be an alternative to tocilizumab.

“Gamot [siya] kontra sa inflammation na may severe arthritis na nakikita na maaaring gamitin sa COVID-19,” Domingo said in a public briefing.

(It is a drug to counter inflammation with severe arthritis that may also be used for COVID-19.)

The drug is in tablet form which makes it easier to produce and be given to a patient.

It is locally available and is less expensive than tocilizumab.

Tocilizumab earlier experienced a shortage in supply in the Philippines, forcing the Department of Health (DOH) to look to other drugs as alternatives.


Subscribe to our daily newsletter

For more news about the novel coronavirus click here.

What you need to know about Coronavirus.

For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next

Don’t miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

For feedback, complaints, or inquiries, contact us.

Source link


Please enter your comment!
Please enter your name here